News | | More »

Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting available at Active Biotech’s website

Press Release

Tasquinimod successfully completes dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort

Press Release

Active Biotech Interim Report Q2 2023

Press Release

Active Biotech enters into clinical trial collaboration agreement for a clinical study with tasquinimod in myelofibrosis

Press Release

Infocus interview with CEO Helen Tuvesson at Redeye Growth Day 2023, June 1

Equity research and Presentations

Safety and ocular biodistribution support development of laquinimod eye drops for inflammatory eye disorders

Press Release

Active Biotech announces positive interim data from an ongoing study with tasquinimod in heavily pre-treated patients with relapsed and refractory multiple myeloma

Press Release

Annual General Meeting of Active Biotech AB

Press Release

New preclinical data on the antifibrotic effects of tasquinimod in myelofibrosis to be presented at EHA 2023

Press Release

Annual Report 2022 Active Biotech AB (publ)

Press Release

Safety and preliminary activity of naptumomab in combination with durvalumab presented at AACR 2023

Press Release

Two recent publications describe the mechanisms by which tasquinimod can act as a potential treatment alternative in multiple myeloma

Publications

Aktiespararna: “Vägskäl närmar sig” (in Swedish)

Equity research and Presentations

Active Biotech confirms positive clinical safety profile of laquinimod eye drops

Press Release

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma

Tasquinimod Publications

CEO Helen Tuvesson presents at Redeye Fight Cancer 2023

Equity research and Presentations

Nasdaq Stockholm
ACTI
Financial Reports
Analyses and Presentations

Investor Relations

Tasquinimod
Laquinimod
Naptumomab

Projects

Company Presentation

We Develop New Treatments for Cancer and Inflammatory Diseases

We leverage our extensive knowledge and previously generated documentation on our assets to develop novel treatments for specialist indications with high medical need and commercial value within cancer and inflammatory eye disorders. We have a stringent focus on our projects in multiple myeloma, uveitis and in solid tumors for naptumomab in partnership with NeoTX.

Novel treatments for specialist indications

Financial Calendar

Interim report Jan-Sep 2023
Date: November 9, 2023

Events

There are no upcoming events.

Pipeline

Disease Area
Discovery
Preclinical
Phase I
Phase II
Phase III
Partner
Hematological malignancies
Tasquinimod Multiple myeloma*
Tasquinimod Myelofibrosis**
Inflammatory eye disorders
Laquinimod eye drops, safety and tolerability
Laquinimod eye drops, ocular biodistribution**
Solid tumors
Naptumomab Combination with docetaxel in non-small cell lung cancer
Naptumomab Combination with anti-PDL1 (durvalumab) in solid tumors
Study ongoing
* In an academic partnership with the Abramson Cancer Center, Philadelphia, University of Pennsylvania
** Study preparations ongoing

Our project portfolio comprises small, orally active immunomodulatory molecules as well as antibody-based immunotherapy. We have three projects in our project portfolio, Tasquinimod, Laquinimod and Naptumomab. Read more about Active Biotechs projects »

Uveitis can Lead to Severe Eye Problems Including Blindness

Laquinimod

Multiple Myeloma a Blood Cancer with Unmet Medical Need

Tasquinimod